Male Breast Cancer: An Experience from a Regional Cancer Centre, Tamil Nadu, India
Introduction: Male breast cancer is rare and accounts for less than 1% of all breast cancers. The incidence continues to rise, and most of the existing literature on male breast cancer consists of retrospective studies. Multicentric and randomised studies are scarce, making it difficult to study the...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Private Limited
2025-03-01
|
| Series: | Journal of Clinical and Diagnostic Research |
| Subjects: | |
| Online Access: | https://jcdr.net/articles/PDF/20795/74882_CE[Ra1]__F(IS)_QC(PS_SS)_PF1(AG_SS)_PFA_NC(IS)_PN(IS).pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Introduction: Male breast cancer is rare and accounts for less than 1% of all breast cancers. The incidence continues to rise, and most of the existing literature on male breast cancer consists of retrospective studies. Multicentric and randomised studies are scarce, making it difficult to study the biology of the disease and effective therapeutic options.
Aim: To investigate the clinicopathologic characteristics and survival outcomes of male breast cancer.
Materials and Methods: This was a cohort study involving the retrospective collection of data from 39 male breast cancer patients, who were included for analysis from a total of 1,871 carcinoma breast cases between January 2018 and October 2022 (data obtained from the Hospital Based Cancer Registry of Government Arignar Anna Memorial Cancer Hospital and Research Institute, Karapettai, Kanchipuram, Tamil Nadu, India). Patient variables related to age, family history, pathological details (including tumour grade, Immunohistochemistry (IHC) and stage of the disease), treatment details and follow-up information were collected for the study. Statistical analysis for survival was performed using Statistical Package for the Social Sciences (SPSS) software version 26.0.
Results: The majority of patients (20 cases) belonged to the 41-60 years age group, with 10% of patients having a family history of cancer. Stage III was the most common stage of presentation, accounting for 15 (38.5%) cases. Luminal A (46.2%) was the most common molecular subtype, followed by Basal type (23.1%). The median Overall Survival (OS) was 46 months (95% CI: 31-40.5-51.5), and the median Disease-Free Survival (DFS) was 44 months (95% CI: 25.21-62.78). Patients with Luminal A subtype had the highest median OS.
Conclusion: Present study concluded that these patients experience an early onset of the disease, with most being hormone receptor positive and commonly presenting in a locally advanced stage. Patients in the Luminal A group have a good prognosis, and survival also depends on the stage of the disease. These groups of patients are unique and heterogeneous among various populations. Although there are many studies comparing male and female breast cancer, the biology of male breast cancer still needs to be studied in detail. There should be a comparison with female breast cancer in prospective randomised multicentric trials to yield therapeutic implications. |
|---|---|
| ISSN: | 2249-782X 0973-709X |